Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CD74 | P04233 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20416780 | 1.00 | ADORA2A (0.49) | ADORA2AADORA2BCYP19A1CD74MIF | |
| SCHEMBL20436589 | 0.90 | ADORA2A (0.51) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20436604 | 0.88 | ADORA2A (0.51) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20436596 | 0.88 | ADORA2A (0.54) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20436595 | 0.87 | ADORA2A (0.62) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL30402211 | 0.87 | ADORA2A (0.49) | ADORA2AADORA2B | |
| SCHEMBL20400534 | 0.87 | ADORA2A (0.49) | ADORA2AADORA2B | |
| SCHEMBL20436598 | 0.85 | ADORA2A (0.49) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20400249 | 0.85 | ADORA2A (0.49) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL30399770 | 0.85 | ADORA2A (0.49) | ADORA2AADORA2BCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768859-A | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-110214012-B | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-05-09 | — | — | CN | disclosed |